Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.

Annals of hematology - 1 Dec 2014

Chen Chih-Cheng, Gau Jyh-Pyng, Chou Hui-Ju, You Jie-Yu, Huang Cih-En, Chen Yi-Yang, Lung Jrhau, Chou Yi-Sheng, Leu Yu-Wei, Lu Chang-Hsien, Lee Kuan-Der, Tsai Ying-Huang

Abstract excerpt

Calreticulin (CALR) mutations were recently identified in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) devoid of JAK2 and MPL mutations. We evaluated the clinical, laboratory, and molecular features of a Taiwanese population of patients with ET. Among 147 ET patients, CALR mutations were detected in 33 (22.5 %), JAK2V617F in 94 (63.9 %), and MPL mutations in 4 (2.7 %). Sixteen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Distribution
Share to Calreticulin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukocyte Count

Share to Platelet Count

Share to Receptors, Thrombopoietin

Share to Splenomegaly

Share to Thrombocythemia, Essential

Share to Thrombophilia

Source

Identifiers

PMID: 25015052
DOI: 10.1007/s00277-014-2151-8

Genes

CALR
JAK2
MPL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.PMID 25015052Read ↗

Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.Semantic proximity Read ↗

[Clinical and biological features of patients with essential thrombocythaemia according to their mutational status JAK2 or CALR: Single-center study of 40 patients and review of the literature].Semantic proximity Read ↗

Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.Semantic proximity Read ↗

Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea.Semantic proximity Read ↗

A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.Semantic proximity Read ↗

CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis.Semantic proximity Read ↗

Analysis of CALR-mutated essential thrombocythemia as a distinct disease entity compared with JAK2 V617F-mutated and triple-negative patients.Semantic proximity Read ↗

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.Semantic proximity Read ↗

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.Semantic proximity Read ↗

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients.Semantic proximity Read ↗

A rare CALR variant mutation and a review of CALR in essential thrombocythemia.Semantic proximity Read ↗

Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.